Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Completed Phase 4 Interventional

Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease

NCT00305903
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine, memantine
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 25, 2026, 2:19 AM EDT
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Phase 1 Interventional

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT04533750
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oral Cavity Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Peposertib
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Not listed Phase 2 Interventional

Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)

NCT01137318
View directory record Official record
Conditions
ADHD
Interventions
Cognitive remediation and Parent Training
Behavioral
Lead sponsor
Queens College, The City University of New York
Other
Eligibility
7 Years to 11 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Flushing, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 25, 2026, 2:19 AM EDT
Terminated Phase 2 Interventional

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

NCT03417882
View directory record Official record
Conditions
Metastatic NSCLC
Interventions
GRN-1201 + Pembrolizumab
Biological
Lead sponsor
BrightPath Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 25, 2026, 2:19 AM EDT
Recruiting Phase 1 Interventional

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

NCT07521046
View directory record Official record
Conditions
Myelofibrosis
Interventions
ropeginterferon alfa- 2b, Ruxolitinib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 25, 2026, 2:19 AM EDT
Withdrawn Phase 1 Interventional

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

NCT05717140
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions
Aerosol Sargramostim, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab
Biological · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

NCT03654768
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
541
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional

New Technique as an Additional Diagnostic Tool for Women Undergoing Neoadjuvant Therapy for Breast Cancer

NCT00566085
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Multisite Prevention of Conduct Problems (Fast Track)

NCT01653535
View directory record Official record
Conditions
Conduct Disorder, Anti-Social Behavior
Interventions
Fast Track
Behavioral
Lead sponsor
Duke University
Other
Eligibility
6 Years to 8 Years
Enrollment
891 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 4 Interventional Results available

Valproate in Late Life Schizophrenia

NCT00194025
View directory record Official record
Conditions
Schizophrenia
Interventions
Valproate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 4 Interventional

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

NCT00191035
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 16 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Pasadena, California • Rolling Hills Estates, California • Spring Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2006 · Synced Oct 25, 2026, 2:19 AM EDT
Active, not recruiting Not applicable Interventional

Digital Therapeutics for Behavior Problems

NCT05647772
View directory record Official record
Conditions
Problem Behavior, Child Behavior
Interventions
UseIt! App, Coach, SmilingMind App
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years to 8 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 3 Interventional Results available

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium 314d Modified Release Tablets, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 25, 2026, 2:19 AM EDT
Recruiting Not applicable Interventional

Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)

NCT05354232
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
2 mA transcranial direct current stimulation (tDCS), 1 mA transcranial direct current stimulation (tDCS), Sham transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 3 Interventional

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

NCT00265837
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 2 Interventional

A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia

NCT01779453
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo, Atorvastatin
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Beta-carotene Absorption and Bioconversion to Vitamin A From Biofortified Cassava Gari

NCT02210507
View directory record Official record
Conditions
Vitamin A Deficiency
Interventions
Biofortified cassava gari, White cassava gari, White cassava gari + red palm oil
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional

Caregiver Implementation Strategies Field Pre-Test

NCT06770036
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Implementation Resource Package for Caregivers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Not applicable Interventional

Treating Sleep in Teens With ADHD

NCT04270812
View directory record Official record
Conditions
ADHD, Sleep
Interventions
Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C)
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 25, 2026, 2:19 AM EDT
Completed Phase 1Phase 2 Interventional

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

NCT00062816
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
ISIS 14803, peginterferon alfa, ribavirin
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 25, 2026, 2:19 AM EDT